20. Higher demand will boost pharmaceutical industry, says CCM
May 29, 2010 by biotechcheck.com · Leave a Comment
20. Higher demand will boost pharmaceutical industry, says CCM
PORT KLANG: Pharmaceutical manufacturer CCM Duopharma Biotech Bhd is optimistic on the outlook of the industry this year, particularly the international market, as demand for better healthcare products is expected to increase.
Read more on The Star
Biotech employment in Florida up 18 percent, report says
May 10, 2010 by biotechcheck.com · Leave a Comment
Biotech employment in Florida up 18 percent, report says
Biotech employment in Florida up 18 percent, report says
Read more on The Palm Beach Post
Increasing ‘Crop Per Drop’ Critical, Says Monsanto’s Fraley
May 4, 2010 by biotechcheck.com · Leave a Comment
Increasing ‘Crop Per Drop’ Critical, Says Monsanto’s Fraley
Speaking before the University of Nebraska’s Water for Food Summit, Monsanto Company Chief Technology Officer Dr. Robb Fraley echoed his company’s commitment to help farmers double crop yields by 2030 while conserving natural resources, all while helping to improve the lives of farmers around the world.
Read more on PR Newswire via Yahoo! Finance
Hot prospects for pepper here, says farmer
April 26, 2010 by biotechcheck.com · Leave a Comment
Hot prospects for pepper here, says farmer
PEPPERCORN farm owner Goh Seng Loong owns the single largest pepper farm in Malaysia and is looking to grow more farms and cultivate some 140-odd hectares in the next three years.
Read more on Business Times
(AFX UK Focus) 2010-04-19 18:50 Genmab says gets 87 mln DKK milestone from GSK
April 21, 2010 by biotechcheck.com · Leave a Comment
(AFX UK Focus) 2010-04-19 18:50 Genmab says gets 87 mln DKK milestone from GSK
COPENHAGEN, April 19 (Reuters) – Danish Biotech firm Genmab said on Monday it would receive an 87 million crown ($16.3 mln) milestone payment from its partner GlaxoSmithKline following European backing for their leukaemia drug Arzerra. In January GlaxoSmithKline and Genmab won European approval for Arzerra, after it was launched in the United States in November. Arzerra is Genmab’s first drug to …
Read more on Interactive Investor


